{"entity":{"id":"manel-juan","kind":"person","name":"Manel Juan","aka":[],"tldr":"The Barcelona immunologist whose team designed ARI-0001 from the hospital's own antibody and made it in-house, so a public hospital could give CAR-T at lower cost.","summary":"Manel Juan is an immunologist in the Department of Immunology at Hospital Clínic de Barcelona and FRCB-IDIBAPS, according to the affiliation on his 2026 HemaSphere paper. The AEMPS's announcement of its February 2021 authorisation of ARI-0001 says a team led by Dr Manel Juan developed the new CD19 CAR-T from the hospital's own monoclonal antibody, and quotes him on a robust, reproducible preparation method that lowers production cost so the therapy can be affordable for academic institutions. He is an author of the CART19-BE-01 and CARTBCMA-HCB-01 reports and of the 2022 Bone Marrow Transplantation article on the hospital exemption route by which ARI-0001 was authorised.","asOf":"2026-11-03","links":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Juan%20M%5BAuthor%5D%20ARI-0001"},{"label":"AEMPS: authorisation of ARI-0001 (10 February 2021)","url":"https://www.aemps.gob.es/informa/la-aemps-autoriza-el-car-t-ari-0001-del-hospital-clinic-para-pacientes-con-leucemia-linfoblastica-aguda/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Immunologist, Department of Immunology, Hospital Clínic de Barcelona and FRCB-IDIBAPS; Universitat de Barcelona","institutionId":"hospital-clinic-barcelona","specialisms":["Immunology","CAR-T design and manufacturing","Advanced therapies"],"profiles":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Juan%20M%5BAuthor%5D%20ARI-0001"},{"label":"AEMPS: authorisation of ARI-0001 (10 February 2021)","url":"https://www.aemps.gob.es/informa/la-aemps-autoriza-el-car-t-ari-0001-del-hospital-clinic-para-pacientes-con-leucemia-linfoblastica-aguda/"}],"papers":[{"title":"The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001","journal":"Bone Marrow Transplantation","year":2022,"doi":"10.1038/s41409-021-01463-y"},{"title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies","journal":"Molecular Therapy","year":2021,"doi":"10.1016/j.ymthe.2020.09.027"},{"title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01)","journal":"The Lancet Oncology","year":2023,"doi":"10.1016/S1470-2045(23)00222-X"},{"title":"Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial","journal":"Frontiers in Immunology","year":2020,"doi":"10.3389/fimmu.2020.00482"}]},"route":"/people/manel-juan/","neighbours":{"institution":[{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/"}],"trial":[{"id":"cart19-be-01","kind":"trial","name":"CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona)","route":"/trials/cart19-be-01/"},{"id":"cartbcma-hcb-01","kind":"trial","name":"CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona)","route":"/trials/cartbcma-hcb-01/"}],"paper":[{"id":"paper-cart19-be-01-mol-ther-2021","kind":"paper","name":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies","route":"/key-papers/paper-cart19-be-01-mol-ther-2021/"},{"id":"paper-cartbcma-hcb-01-lancet-oncol-2023","kind":"paper","name":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","route":"/key-papers/paper-cartbcma-hcb-01-lancet-oncol-2023/"},{"id":"paper-trias-hospital-exemption-ari-0001-bmt-2022","kind":"paper","name":"The hospital exemption pathway for advanced therapies and the case of the CAR-T ARI-0001","route":"/key-papers/paper-trias-hospital-exemption-ari-0001-bmt-2022/"}]}}